The Future of Biosimilars 2015 offers expert insight and opinion on the key issues facing the high risk, high reward biosimilars market: how the market is performing, where the market is headed and which key milestones are being monitored.
Gain insights on the recent market events, the current biosimilar and non-comparable biologics (NCB) pipeline and what experts believe are the key remaining uncertainties in the biosimilars market. In addition, receive an Advisory Highlights management summary which covers key findings from the report.
Since the first edition of FirstWord’s The Future of Biosimilars, the opportunities and challenges that biosimilars represent to companies, patients, physicians and health services have continued to dominate discussions around the globe.
The Future of Biosimilars 2015 summarises, analyses and gives insight into the opportunities and challenges biosmilars developers face today.
The biosimilars market is evolving quickly, making Future of Biosimilars 2015 a must-read reference not only for those working in biosimilars competitive intelligence, brand strategy, business development and licensing, but also brand forecasting, market research and financial analytics.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
![]() Part of the FirstWord Dossier family of reports exploring important trends and challenging issues affecting pharma, FirstWord Dossier Advisory Reports and Highlights provide actionable insights derived from deep-dive primary research with thought leaders from across the stakeholder spectrum through an in-depth report and a management summary of key findings ensuring clients are up to speed and can bring others up to speed quickly. |
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved